CN116457344B - 低分子量蛋白质降解剂及其应用 - Google Patents
低分子量蛋白质降解剂及其应用Info
- Publication number
- CN116457344B CN116457344B CN202180067832.3A CN202180067832A CN116457344B CN 116457344 B CN116457344 B CN 116457344B CN 202180067832 A CN202180067832 A CN 202180067832A CN 116457344 B CN116457344 B CN 116457344B
- Authority
- CN
- China
- Prior art keywords
- compound
- alkyl
- cancer
- methyl
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PLPCT/PL2020/000066 | 2020-08-03 | ||
| PL2020000066 | 2020-08-03 | ||
| PCT/EP2021/071694 WO2022029138A1 (en) | 2020-08-03 | 2021-08-03 | Low molecular weight protein degraders and their applications |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116457344A CN116457344A (zh) | 2023-07-18 |
| CN116457344B true CN116457344B (zh) | 2026-05-12 |
Family
ID=72193535
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202180067832.3A Active CN116457344B (zh) | 2020-08-03 | 2021-08-03 | 低分子量蛋白质降解剂及其应用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240294489A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4188373A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023541522A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230048373A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116457344B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021319847A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023001956A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3186919A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL300308A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023001401A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022029138A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117440948A (zh) * | 2021-06-28 | 2024-01-23 | 成都分迪药业有限公司 | 酰胺类化合物及其用途 |
| CN114933584B (zh) * | 2021-08-09 | 2022-12-27 | 上海贵之言医药科技有限公司 | 一种二氢-2h-异吲哚酯类化合物 |
| CN116082301A (zh) * | 2021-11-05 | 2023-05-09 | 上海美志医药科技有限公司 | 具有降解gspt1活性的化合物及其应用 |
| WO2023085785A1 (ko) * | 2021-11-09 | 2023-05-19 | 한국화학연구원 | 글루타이미드 모핵을 갖는 이소인돌리논 유도체 및 이의 용도 |
| AU2022405474B2 (en) * | 2021-12-08 | 2026-08-13 | Gluetacs Therapeutics (Shanghai) Co., Ltd. | E3 ubiquitin ligase ligand compound, protein degrader developed based thereon and their applications |
| CN118488948A (zh) | 2021-12-22 | 2024-08-13 | 吉利德科学公司 | Ikaros锌指家族降解剂及其用途 |
| US20240124412A1 (en) * | 2021-12-22 | 2024-04-18 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| PL4245756T3 (pl) | 2022-03-17 | 2025-02-17 | Gilead Sciences, Inc. | Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania |
| CN114835680A (zh) * | 2022-04-29 | 2022-08-02 | 成都分迪药业有限公司 | 卤素取代异吲哚啉化合物及其应用 |
| CN115636811A (zh) * | 2022-08-17 | 2023-01-24 | 成都分迪药业有限公司 | 异吲哚啉苄胺衍生物的合成方法 |
| JP2025531869A (ja) | 2022-09-09 | 2025-09-25 | イノヴォ セラピューティクス、インコーポレイテッド | CK1αおよびDUAL CK1α/GSPT1分解化合物 |
| WO2024096753A1 (en) | 2022-11-02 | 2024-05-10 | Captor Therapeutics S.A. | Nek7 degraders and methods of use thereof |
| WO2025179161A1 (en) | 2024-02-21 | 2025-08-28 | Innovo Therapeutics, Inc. | Protein degrading compounds |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102112463A (zh) * | 2008-05-30 | 2011-06-29 | 细胞基因公司 | 5-取代的异二氢吲哚化合物 |
| WO2017197056A1 (en) * | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Bromodomain targeting degronimers for target protein degradation |
| WO2018169777A1 (en) * | 2017-03-14 | 2018-09-20 | Biotheryx, Inc. | Compounds targeting proteins, compositions, methods, and uses thereof |
| WO2019241274A1 (en) * | 2018-06-13 | 2019-12-19 | Biotheryx, Inc. | Aminoamide compounds |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| US6306663B1 (en) | 1999-02-12 | 2001-10-23 | Proteinex, Inc. | Controlling protein levels in eucaryotic organisms |
| US7323479B2 (en) | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
| AU2007290407A1 (en) * | 2006-08-30 | 2008-03-06 | Celgene Corporation | 5-substituted isoindoline compounds |
| HUE035389T2 (en) | 2006-09-26 | 2018-05-02 | Celgene Corp | 5-substituted quinazolinone derivatives as anticancer agents |
| SG183257A1 (en) | 2010-02-11 | 2012-09-27 | Celgene Corp | Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same |
| US8927725B2 (en) * | 2011-12-02 | 2015-01-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Thio compounds |
| US9499514B2 (en) * | 2014-07-11 | 2016-11-22 | Celgene Corporation | Antiproliferative compounds and methods of use thereof |
| CN121974842A (zh) | 2016-05-10 | 2026-05-05 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| CN109562107A (zh) * | 2016-05-10 | 2019-04-02 | C4医药公司 | 用于靶蛋白降解的杂环降解决定子体 |
| IL319363A (en) * | 2017-01-31 | 2025-05-01 | Arvinas Operations Inc | Cervalon ligands and bifunctional compounds containing them |
| EP4717317A3 (en) | 2017-06-20 | 2026-06-03 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| JP7258009B2 (ja) | 2017-07-10 | 2023-04-14 | セルジーン コーポレイション | 抗増殖化合物及びその使用方法 |
| TWI793151B (zh) * | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途 |
| CA3075813A1 (en) * | 2017-10-04 | 2019-04-11 | Dana-Farber Cancer Institute, Inc. | Small molecule inhibition of transcription factor sall4 and uses thereof |
| EA202191833A1 (ru) * | 2018-12-31 | 2021-10-11 | Селджин Корпорейшн | Композиции и способы применения 2-(4-хлорфенил)-n-((2-(2,6-диоксопиперидин-3-ил)-1-оксоизоиндолин-5-ил)метил)-2,2-дифторацетамида |
-
2021
- 2021-08-03 AU AU2021319847A patent/AU2021319847A1/en active Pending
- 2021-08-03 JP JP2023507550A patent/JP2023541522A/ja active Pending
- 2021-08-03 EP EP21758624.7A patent/EP4188373A1/en active Pending
- 2021-08-03 CN CN202180067832.3A patent/CN116457344B/zh active Active
- 2021-08-03 CA CA3186919A patent/CA3186919A1/en active Pending
- 2021-08-03 IL IL300308A patent/IL300308A/en unknown
- 2021-08-03 KR KR1020237007785A patent/KR20230048373A/ko active Pending
- 2021-08-03 WO PCT/EP2021/071694 patent/WO2022029138A1/en not_active Ceased
- 2021-08-03 MX MX2023001401A patent/MX2023001401A/es unknown
- 2021-08-03 US US18/040,383 patent/US20240294489A1/en active Pending
- 2021-08-03 BR BR112023001956A patent/BR112023001956A2/pt unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102112463A (zh) * | 2008-05-30 | 2011-06-29 | 细胞基因公司 | 5-取代的异二氢吲哚化合物 |
| WO2017197056A1 (en) * | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Bromodomain targeting degronimers for target protein degradation |
| WO2018169777A1 (en) * | 2017-03-14 | 2018-09-20 | Biotheryx, Inc. | Compounds targeting proteins, compositions, methods, and uses thereof |
| WO2019241274A1 (en) * | 2018-06-13 | 2019-12-19 | Biotheryx, Inc. | Aminoamide compounds |
Non-Patent Citations (1)
| Title |
|---|
| STN REG数据库 .STN REG数据库 .2020, * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116457344A (zh) | 2023-07-18 |
| MX2023001401A (es) | 2023-05-03 |
| JP2023541522A (ja) | 2023-10-03 |
| CA3186919A1 (en) | 2022-02-10 |
| AU2021319847A1 (en) | 2023-03-02 |
| EP4188373A1 (en) | 2023-06-07 |
| US20240294489A1 (en) | 2024-09-05 |
| KR20230048373A (ko) | 2023-04-11 |
| IL300308A (en) | 2023-04-01 |
| BR112023001956A2 (pt) | 2023-02-28 |
| WO2022029138A1 (en) | 2022-02-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN116457344A (zh) | 低分子量蛋白质降解剂及其应用 | |
| US11859014B2 (en) | Peptidomimetics for the treatment of Norovirus infection | |
| TWI851542B (zh) | Shp2之八氫環戊烷并[c]吡咯別構抑制劑 | |
| AU2015276537B2 (en) | Novel compounds as dual inhibitors of histone methyltransferases and dna methyltransferases | |
| CN115989223B (zh) | 使用CCR8抑制剂靶向Tregs的方法和组合物 | |
| TW202341983A (zh) | 用於降解突變kras蛋白之化合物及其應用 | |
| JP5886411B2 (ja) | 新規のピリミジン誘導体 | |
| WO2020160198A1 (en) | Compounds and uses thereof | |
| US20040152759A1 (en) | Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders | |
| KR20120055571A (ko) | 종양성 또는 자가면역 질환 치료용 전구약물로서의 푸라자노벤즈이미다졸 | |
| US20220002291A1 (en) | Proteolysis-targeting chimeras | |
| JP6314128B2 (ja) | 新たなアルキル化剤 | |
| CN113614095A (zh) | 作为精氨酸酶抑制剂的烷基硼酸类化合物 | |
| RU2632199C2 (ru) | Функционализированные производные тиеноиндола для лечения ракового заболевания | |
| JPWO2016039398A1 (ja) | 含窒素複素環誘導体、神経保護剤及び癌治療用医薬組成物 | |
| CN115003650A (zh) | 二取代金刚烷基衍生物、其药学上可接受的盐及包含其作为有效成分的用于抑制癌生长的药物组合物 | |
| CN114390924A (zh) | 用于蛋白质降解的化合物、组合物和方法 | |
| CN118852335A (zh) | 噻二唑烷酮衍生物及其制备方法和应用 | |
| EP3969450B1 (en) | Quinazoline-2,4-dione derivatives as parp inhibitors | |
| CN103450062B (zh) | 一种治疗肿瘤的双靶点药物化合物及其制备方法和用途 | |
| CN121045188A (zh) | 1,2-二氢吡咯并[1,2-a]吡嗪-3(4H)-酮衍生物及其用途 | |
| HK40062378B (en) | Quinazoline-2,4-dione derivatives as parp inhibitors | |
| HK40062378A (en) | Quinazoline-2,4-dione derivatives as parp inhibitors | |
| HK1120406A (en) | Combination administration of an indolinone with a chemotherapeutic agent for cell proliferation disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |